MedPath

Iberdomide

Generic Name
Iberdomide
Drug Type
Small Molecule
Chemical Formula
C25H27N3O5
CAS Number
1323403-33-3
Unique Ingredient Identifier
8V66F27X44
Background

Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.

Clinical Trials
Related News

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Phase 2
Completed
Conditions
Lupus Erythematosus, Systemic
Interventions
Other: Placebo
First Posted Date
2017-05-19
Last Posted Date
2023-06-15
Lead Sponsor
Celgene
Target Recruit Count
289
Registration Number
NCT03161483
Locations
🇺🇸

North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States

🇺🇸

University Of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States

and more 181 locations

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2017-05-01
Last Posted Date
2017-07-02
Lead Sponsor
Celgene
Target Recruit Count
16
Registration Number
NCT03135509
Locations
🇺🇸

Quintiles Phase One Services, LLC, Overland Park, Kansas, United States

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2016-07-01
Last Posted Date
2016-10-18
Lead Sponsor
Celgene Corporation
Target Recruit Count
36
Registration Number
NCT02820935
Locations
🇺🇸

PPD Development, LP, Austin, Texas, United States

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2016-05-16
Last Posted Date
2024-06-25
Lead Sponsor
Celgene
Target Recruit Count
466
Registration Number
NCT02773030
Locations
🇺🇸

Local Institution - 101, Atlanta, Georgia, United States

🇺🇸

Local Institution - 108, Hackensack, New Jersey, United States

🇺🇸

Local Institution - 115, Boston, Massachusetts, United States

and more 86 locations

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Placebo
First Posted Date
2014-07-09
Last Posted Date
2020-03-19
Lead Sponsor
Celgene
Target Recruit Count
42
Registration Number
NCT02185040
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Arizona Arthritis and Rheumatology Research, PLLC, Paradise Valley, Arizona, United States

🇺🇸

UCSD Center for Innovative Therapy, La Jolla, California, United States

and more 32 locations

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2014-01-13
Last Posted Date
2014-01-13
Lead Sponsor
Celgene Corporation
Target Recruit Count
64
Registration Number
NCT02034773
Locations
🇺🇸

Covance Clinical Research Unit, Madison, Wisconsin, United States

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: CC-220 2 mg
Drug: CC-220 0.03 mg
Drug: CC-220 0.1 mg
Drug: CC-220 0.3 mg
Drug: CC-220 1 mg
Drug: Placebo
First Posted Date
2012-11-27
Last Posted Date
2019-11-12
Lead Sponsor
Celgene
Target Recruit Count
65
Registration Number
NCT01733875
Locations
🇺🇸

Covance Clinical Research Unit, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy